Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

(2013) M. A. Dimopoulos et al.   BLOOD

Subcutaneous Bortezomib

(2013) Sheridan M. Hoy   DRUGS

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells

(2013) Miho Nara et al.   PLoS One

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

(2013) Bo Hu et al.   PLoS One

Proteasome inhibitors in mantle cell lymphoma

(2012) Beata Holkova et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma

(2012) Dehui Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I/II Study of Velcade®-Beam (V-Beam) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Indolent Non-Hodgkin'S Lymphoma (NHL), Transformed or Mantle Cell Lymphoma (MCL)

(2012) B.M. William et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

(2012) Z. Tian et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF

(2012) Chun-Yan Sun et al.   CARCINOGENESIS

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Dual Inhibition of Canonical and Noncanonical NF- B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

(2012) C. Fabre et al.   CLINICAL CANCER RESEARCH

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

(2012) Elisa Gallerani et al.   EUROPEAN JOURNAL OF CANCER

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

(2012) Enrique M Ocio et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Molecular Model of the Human 26S Proteasome

(2012) Paula C.A. da Fonseca et al.   MOLECULAR CELL

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

(2012) N Amodio et al.   Cell Death & Disease

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

(2011) J. D. Shaughnessy et al.   BLOOD

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

(2011) Y. X. Zhu et al.   BLOOD

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs

(2011) Claudia P. Miller et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells

(2011) Alyson J. Smith et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression

(2011) Mu Hao et al.   LEUKEMIA & LYMPHOMA

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia

(2010) A. M. Roccaro et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

(2010) Siquan Chen et al.   CANCER RESEARCH

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation

(2010) Chunyang Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

(2010) Annemiek Broyl et al.   LANCET ONCOLOGY

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (

(2010) Christopher P. Venner et al.   LEUKEMIA & LYMPHOMA

Characterization of bortezomib-adapted I-45 mesothelioma cells

(2010) Lidong Zhang et al.   Molecular Cancer

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention

(2009) Vasilis P Androutsopoulos et al.   BMC CANCER

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

(2009) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

(2009) Han-Jie Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

(2008) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

Bortezomib in the front-line treatment of multiple myeloma

(2008) Paul G Richardson et al.   Expert Review of Anticancer Therapy

Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

(2008) Owen A. O'Connor et al.   LEUKEMIA & LYMPHOMA

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

(2008) H. Gu et al.   MOLECULAR CANCER THERAPEUTICS